DNA - Ginkgo Bioworks Holdings Inc

6.5
-0.340   -5.231%

Share volume: 935,860
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.19%

PREVIOUS CLOSE
CHG
CHG%
$6.84
-0.34
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 32%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-7.80%
1 Month
-35.96%
3 Months
-30.85%
6 Months
-41.91%
1 Year
-13.79%
2 Year
-28.65%
Key data
Stock price
$6.50
P/E Ratio 
0.00
DAY RANGE
$6.34 - $6.64
EPS 
-$6.40
52 WEEK RANGE
$5.00 - $17.58
52 WEEK CHANGE
-$6.47
MARKET CAP 
503.505 M
YIELD 
N/A
SHARES OUTSTANDING 
61.924 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$1,590,017
AVERAGE 30 VOLUME 
$1,401,433
Company detail
CEO: Jason Kelly
Region: US
Website: ginkgobioworks.com
Employees: 640
IPO year: 2021
Issue type:
Market: NYSE
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Recent news